Supported claims indicate that Moderna’s intismeran autogene, an mRNA vaccine tested with Merck’s Keytruda in a phase 3 trial, met primary and secondary endpoints by extending recurrence-free survival and reducing metastasis risk in post-surgical melanoma patients. Unverified reports cite approximately 112,000 new U.S. cases and over 8,500 deaths annually. Data on exact survival metrics remain undisclosed pending a future medical meeting.